The initial chapters of this report provide an orientation of drug deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine and stem cells deal making since 2009, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all bio pharma companies.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain.
In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z, deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Web link to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, thi
Copyright©2012 Vocus, Inc.
All rights reserved